NeOnc Technologies Appoints David Choi as Chief Accounting Officer
NeOnc Technologies Appoints David Choi as Chief Accounting Officer: Implications for Investors
Key Developments
-
David Choi appointed as Chief Accounting Officer at NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), effective March 13, 2026.
-
NeOnc is a multi-Phase 2 clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers.
-
Mr. Choi is tasked with overseeing accounting, financial reporting, internal controls, and corporate governance as the company expands globally.
-
The appointment comes at a critical inflection point as NeOnc accelerates clinical trials and prepares for further corporate growth.
Leadership Commentary
Amir Heshmatpour, Chairman and CEO: “David’s extensive expertise in technical accounting and financial reporting for public companies comes at a pivotal time for NeOnc. As we accelerate our clinical trials and prepare for the next stages of corporate growth, maintaining rigorous financial controls and governance is essential. David’s proven track record at top-tier advisory firms makes him an invaluable addition to our leadership team as we strive to deliver novel therapies to patients with CNS cancers.”
David Choi: “I am honored to join NeOnc at such an exciting inflection point in its development. NeOnc is doing vital work in the fight against aggressive brain cancers, and I look forward to applying my experience in financial infrastructure and compliance to support the Company’s strategic objectives. My focus will be on ensuring we have the robust financial foundation necessary to support our clinical advancements and drive long-term value for our shareholders.”
Background on David Choi
-
Over a decade of experience in accounting, financial reporting, and internal controls for both public and private companies.
-
Former Director at Blythe Global Advisors, advising companies on technical accounting, SEC reporting, SOX compliance, and financial transformations.
-
Led engagements for financial reporting transformation, internal control design and implementation, and accounting for complex transactions (equity instruments, debt financing, business combinations).
-
Previous roles at Grant Thornton and Ernst & Young, providing assurance and advisory services, financial statement audits, technical accounting advisory, and SOX compliance.
-
Certified Public Accountant (CPA), with a Master of Professional Accountancy and Bachelor of Arts in Business Economics (minor in Accounting) from UC Irvine.
Corporate Overview & Pipeline
-
NeOnc specializes in CNS therapeutics targeting the blood-brain barrier challenge.
-
NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods, with patent protections extending to 2038.
-
Proprietary chemotherapy agents have shown positive effects in laboratory tests and clinical trials, specifically in treating malignant gliomas.
-
NEO100™ and NEO212™ therapeutics are currently in Phase II human clinical trials and advancing under FDA Fast-Track and IND status.
-
NeOnc has exclusive global licenses from the University of Southern California for patents related to NEO100, NEO212, and other pipeline products for oncological and neurological conditions.
Forward-Looking Statements and Risks
-
The release contains forward-looking statements regarding future expectations, projections, and potential outcomes.
-
Risks highlighted:
-
Preclinical and early clinical trial results may not predict future trial outcomes.
-
Announced or published clinical trial data may change as more patient data emerges and undergoes audit and verification.
-
NeOnc’s product candidates are in preclinical and clinical stages, not approved for commercial sale, and may never receive regulatory approval or become commercially viable.
-
Investors are urged to review all risk factors and cautionary language in NeOnc’s SEC filings, including its latest 10-Q.
Potential Share Price Sensitivity
-
The appointment of David Choi as Chief Accounting Officer signals strengthening of financial controls and governance at a pivotal moment for NeOnc’s clinical and corporate expansion.
-
Successful advancement of Phase II clinical trials (NEO100™ and NEO212™) under FDA Fast-Track and IND status may drive positive investor sentiment and potential share price appreciation, subject to trial outcomes and regulatory milestones.
-
Patent protections to 2038 and exclusive global licenses position NeOnc for long-term competitive advantages in CNS therapeutics.
-
However, significant risks remain regarding trial outcomes, regulatory approvals, and commercialization potential, which could materially impact share value.
Contact Information
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. The information herein is based on public disclosures and may contain forward-looking statements subject to risks and uncertainties. Past performance is not indicative of future results. NeOnc Technologies’ product candidates are not approved for commercial sale and may never receive regulatory approval. The company assumes no obligation to update forward-looking statements except as required by law.
View NEONC TECHNOLOGIES HOLDINGS, INC. Historical chart here
